Nichole Tucker

Patritumab deruxtecan has been granted a breakthrough therapy designation by the FDA to accelerate its development for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies.

In an interview with Targeted Oncology, Matthew T. Campbell, MD, discussed unmet needs for patients with renal cell carcinoma and sarcomatoid dedifferentiation. He also explained how to approach the treatment of patients with challenging non-clear cell tumors.

Cristiane D. Bergerot, PhD, discussed factors contributing to financial toxicity in patients with RCC and how it impacts oncology care providers.

Andreana Holowatyj, PhD, MSCI, discusses the characteristics of appendiceal cancer and what differentiates it from colorectal cancer.

In an interview with Targeted Oncology™, Clayton Lau, MD, discussed the impact of COVID-19 on managing genitourinary cancers.

Andrea Holowatyj, PhD, MSCI delved into the growing issue of early-onset appendiceal cancer, how it impacts certain groups, and what efforts can improve outcomes for these patients in the future.

Following an orphan drug designation earlier in 2021, NUV-422 has been granted a fast track designation for the treatment of high-grade gliomas.

All 248 patients with endometrial cancer have been enrolled in the phase 3 SIENDO clinical trial.

The XVd regimen appears effective at prolonging progression-free survival with decreased toxicity when administered at lower doses of selinexor or the standard dose.

The XVd regimen demonstrated comparable efficacy and safety in patients with multiple myeloma who had high-risk or standard-risk cytogenetic features.

The combination of obinutuzumab with polatuzumab vedotin, or lenalidomide may be a solution for the toxicity sometimes observed with chimeric antigen receptor T cells in patients with follicular lymphoma.

The Ocomine Dx Target Test is now FDA-approved to help identify eligible patients to be treated with amivantamab.

ST101, an agent being investigated in a phase 1/2 clinical trial, has been granted fast track designation from the FDA for the treatment of patients with glioblastoma multiforme.

Navel G. Daver, MD, discusses the molecular characteristics of acute myeloid leukemia, agents available for the treatment of mutated acute myeloid leukemia, and how to potentially improve treatment in the future.

The post-marketing requirements for duvelisib are no longer necessary, according to the FDA, and the agent has been withdrawn from the United States market for the treatment of patients with relapsed or refractory follicular lymphoma.

Pembrolizumab for stage IIB or IIC melanoma has been granted approval by the FDA.

In the phase 3 ARASENS study, the use of darolutamide with docetaxel and androgen deprivation therapy demonstrated an overall survival advantage for patients with metastatic hormone-sensitive prostate cancer.

Rituximab in combination with chemotherapy is now FDA approved for the treatment of pediatric patients with 4 types of hematologic malignancies.

Luspatercept-aamt for the treatment of anemia in adult patients with non-transfusion dependent beta thalassemia is on track to receive an FDA approval indication.

In the phase 3 IMforte clinical trial, researchers are exploring lurbinectedin and atezolizumab as induction and maintenance therapy for patients with extensive-stage small cell lung cancer.

The FDA has decided not to approve plinabulin with granulocyte colony-stimulating factor for the prevention of chemotherapy-induce neutropenia until further research is conducted.

Rajneesh Nath provides an expert's take on the evolution of risk stratification, molecular testing, and treatment of acute myeloid leukemia.

Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.

Findings from the phase 3 OlympiA led to the filing of a supplemental new drug application for olaparib as adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer.

In an interview with Targeted Oncology, Ruben Niesvizky, MD, discussed current efficacy outcomes in multiple myeloma and how the introduction of the car-BIRD regimen may improve upon them.

Efficacy signals have been shown in 100% of patients with metastatic prostate cancer treated with a new formulation of cabazitaxel.

After 40 years, a novel agent may be on the fast track to becoming the first drug to improve the standard of care for patients with metastatic colorectal cancer.

A novel chimeric antigen receptor T-cell agent will now be developed in the United States following an orphan drug designation granted by the FDA.

Results from the phase 3 AGENT study are awaited after the FDA granted fast track designation to arfolitixorin for advanced colorectal cancer treatment.

The community oncology organization, Tennessee Oncology, reportedly saved Medicare $5 million between 2019 and 2020.